Analyst Reco. Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
3.28 ^USD	-2.53%		-16.54%	+62.38%

04-29	Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	MT
04-29	Transcript : Aquestive Therapeutics, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	04-11	MT
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	03-28	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	03-20	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	03-18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	03-15	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	03-11	MT
Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	03-07	MT
HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	11-08	MT
Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	10/08/23	MT
Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	03/07/23	MT
Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	09/03/23	MT
Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	31/01/23	MT
Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	04/11/22	MT
Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	07/09/22	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	06/09/22	MT
BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	01/09/22	MT
Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	30/08/22	MT
Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	04/08/22	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	21/06/22	MT
HC Wainwright Adjusts Aquestive Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	31/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Analyst Reco.

Filters